Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol

Karen Matvienko-Sikar, Kerry Avery, Jane Blazeby, Karen Hughes, Pamela Jacobsen, Jamie Kirkham, Jan Kottner, Katie Mellor, Ian Saldanha, Valerie Smith, Caroline Terwee, Paula Williamson

Research output: Contribution to journalArticlepeer-review

79 Downloads (Pure)

Abstract

Background: Outcome heterogeneity, selective reporting, and
choosing outcomes that do not reflect needs and priorities of
stakeholders, limit the examination of health intervention effects,
particularly in late phase trials. Core outcome sets (COS) are a
proposed solution to these issues. A COS is an agreed-upon,
standardised set of outcomes that should be measured and reported
as a minimum in all trials in a specific area of health or healthcare.
COS are intended to increase standardisation of outcome
measurement and reporting to better enable comparisons between,
and synthesis of findings of trials in a particular health area.
Methods: This study will examine late phase trials, published between
October 2019 and March 2020 (inclusive), in the following five medical
journals: New England Journal of Medicine, Journal of the American
Medical Association, Lancet, BMJ, and Annals of Internal Medicine. Trials
will be examined to determine if they refer to a COS, and whether they
use a COS. Trialists for each identified trial will subsequently be
contacted to complete an online survey examining trialists’ awareness
of, and decisions to search for and use a COS.
Discussion: This study will provide important information on uptake
of COS by later phase trialists in major medical journals, and the views
of these trialists on COS use in trials. These findings will inform
approaches to increasing awareness and uptake of COS in future
health trials.
Original languageEnglish
Number of pages5
JournalHRB Open Research
Volume3
Issue number53
DOIs
Publication statusPublished - 25 Feb 2021

Fingerprint

Dive into the research topics of 'Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol'. Together they form a unique fingerprint.

Cite this